Stocks making the biggest moves midday: Micron, Paramount Skydance, Mara Holdings, PepsiCo & more

Micron surged more than 7% after announcing up to $3B in U.S. semiconductor supply-chain investment, while Cerebras jumped ~11% on a major European expansion targeting ~2,000MW total capacity by 2027. On the downside, AstraZeneca fell ~6% after its Wainua heart-disease drug missed a late-stage trial endpoint and Paramount Skydance slid ~6% as multiple states consider an anti-trust lawsuit over its Warner Bros. Discovery deal. In consumer names, PepsiCo reported slightly weaker adjusted EPS ($2.20 vs $2.21 expected) alongside higher revenue ($24.18B vs $23.95B), and Costco shares fell 4% on decelerating June comps (+8.8% vs +12.5% in May).

Analysis

The market is rewarding anything that looks like scarce capacity in AI and semis, but the real signal is that policy-backed spend is starting to act like an earnings backstop for domestic infrastructure, not just a PR line item. That supports MU at the multiple level more than the P&L level today; the deeper beneficiary set is U.S. tool, materials, and packaging vendors, while Chinese-exposed memory peers still carry a higher geopolitical discount. CBRS is the more fragile version of the same trade: the power/land buildout is long-duration optionality, but monetization only matters if it converts into signed demand before capital intensity drags returns.

The pharma/diagnostics tape is telling you capital is rotating toward cleaner catalyst paths. QGEN screens as a classic sponsor-led rerating where the first leg is easy and the second leg depends on whether a real bid materializes; without filing momentum, the 10% move is mostly optionality premium. AZN is the opposite: a late-stage miss usually inflicts more damage on confidence than on near-term revenue, and the spillover is a higher hurdle for single-asset biotech names and XBI-style exposure over the next 1-3 months.

On consumer, the market is starting to punish companies whose premium valuation depends on persistent traffic or pricing power. COST and PEP both look vulnerable to multiple compression if deceleration persists into the next read-through, because investors will infer that household spend is normalizing faster than expected; that opens relative-value shorts against broader staples rather than absolute bear cases. CRM is the cleanest short-term downside setup because downgrade-driven sentiment often persists until the next bookings/cRPO proof point; if those metrics do not reaccelerate, the stock can underperform even in a stable tape.

Key Decisions for Investors

• Buy MU on pullbacks or use a 1-3 month call spread via SMH/SOXX exposure; thesis is policy/sovereign support for domestic semicap capex, with the trade invalidated if the next guide does not show better forward demand or if CHIPS-related awards stall.
• Treat CBRS as a small-sized momentum call, not a core fundamental long: buy only on weakness and only if management can show pre-leasing or contracted capacity in the next 1-2 quarters; otherwise expect the stock to give back the move as capex math catches up.
• Fade CRM rallies with 1-3 month put spreads or a tactical short into strength; risk/reward favors downside if bookings and cRPO checks stay soft, and the thesis breaks only on a clear reacceleration in forward indicators.
• Do not chase QGEN until there is a formal bid or financing detail; if no filing appears within 2-4 weeks, fade the rumor premium. If a cash offer is announced, pair long QGEN vs XBI to isolate deal spread.
• Short PEP or COST versus XLP on strength as a valuation-compression trade; both need continued pricing power to justify premium multiples, and a second consecutive deceleration in comps/mix would likely force estimates and multiples lower.